khawla abu hammour
@ju.edu.jo
University of Jordan
Scopus Publications
- Cost Savings in Oncology Chemotherapy: The Role of Vial Sharing in Centralized Preparation
Khawla Abu Hammour, Alaa Almomani, Aya Allan, Mohammad Ballout, Mariam Abdel Jalil, et al.
Value in Health Regional Issues, 2026 - Factors affecting pharmacy and medical students knowledge and attitude towards respiratory syncytial virus vaccines
Khawla Abu Hammour, Faris El-Dahiyat, Fahmi Y. Al-Ashwal, Qusai Manaseer, Walid Abu Hammour, et al.
Currents in Pharmacy Teaching and Learning, 2026 - Health technology assessment in Jordan: current landscape, challenges, and future roadmap
Khawla Abu Hammour, Faris El-Dahiyat, Zaheer-Ud-Din Babar, Fahmi Y. Al-Ashwal, Rana K. Abu-Farha
Journal of Pharmaceutical Policy and Practice, 2026 - Healthcare Applications of Artificial Intelligence
Faris El-Dahiyat, Meriam Alomari, Khawla Abu Hammour, Rima Heider Al Omari, Ghaleb El Refae
Lecture Notes in Networks and Systems, 2026 - Prevalence of diabetes distress and its association with medication adherence and diabetes control among patients with type 2 diabetes mellitus in Egypt and Jordan
Mohamed Hassan Elnaem, Muna Barakat, Merna Mahmoud Abou Khatwa, Khawla Abu-Hammour, Yasmeen Barakat, et al.
Critical Public Health, 2026 - Carbapenem De-escalation in urinary tract infections: prevalence and outcomes among hospitalized patients
Leedia Abuelshayeb, Rana Abu-Farha, Khawla Abu Hammour, Mohammed Zawiah
BMC Infectious Diseases, 2025 - Escherichia coli and MSSA urinary tract infections: Carbapenem de-escalation challenges and outcomes
Rana K Abu-Farha, Lobna Gharaibeh, Rama Alkhawaldeh, Khawla Abu Hammour, Ammena Y Binsaleh, et al.
Electronic Journal of General Medicine, 2025
This retrospective study evaluated carbapenem de-escalation in urinary tract infection patients with <i>Escherichia coli </i>(<i>E. coli</i>) or Methicillin-sensitive Staphylococcus aureus (MSSA) at Jordan University Hospital from January 2019 to July 2021. Among 398 patients who received empiric carbapenem therapy, 94 (23.6%) had positive urine cultures. Specifically, 67 patients had <i>E. coli</i>, 11 had MSSA, and 16 had both pathogens, with most (83%) having infections with a single organism. Only 9.6% of patients underwent successful de-escalation to a narrower-spectrum antibiotic within 48 hours of culture results, while 2.1% were incorrectly de-escalated. Interestingly, those who were successfully de-escalated had a longer median hospital stay (27 days, inter-quartile range [IQR] = 24) compared to those who failed or were incorrectly de-escalated (median = 9 days, IQR = 10) (p = 0.004). The low rate of de-escalation may reflect physicians’ reluctance to switch from broad-spectrum to narrow-spectrum antibiotics. Additionally, the longer hospital stays associated with successful de-escalation suggest the presence of underlying clinical factors influencing physicians’ behavior. - Prevalence, Appropriateness, and Outcomes of Colistin Use in Multidrug-Resistant Pseudomonas aeruginosa Infections: Insights from Hospital Data
Rana K. Abu-Farha, Savana Sobh, Khawla Abu Hammour, Feras Darwish El-Hajji, Sireen A. Shilbayeh, et al.
Medicina Lithuania, 2025
Background and Objectives: This study aimed to assess the prevalence of colistin prescriptions among patients with multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) infections admitted to a tertiary teaching hospital in Jordan. Additionally, the study evaluated the appropriateness of colistin prescriptions and assessed resistance levels of this strain. Materials and Methods: In this retrospective study, adult patients who were infected with MDR P. aeruginosa and were admitted to Jordan University Hospital between January 2018 and March 2024 were included. Data on demographics, clinical characteristics, sources of infection, antibiotic therapy, and clinical outcomes were collected. Results: Out of the 85 patients who met the inclusion criteria for having MDR P. aeruginosa, colistin was administered to 16 patients (18.8%). Notably, approximately two-thirds (68.7%) of the isolates from patients who received colistin were classified as extensively drug-resistant (XDR). Among the isolates, 15 out of 16 (93.8%) were resistant to both ciprofloxacin and imipenem. Among the patients requiring colistin, five (31.3%) discontinued therapy, while two (12.5%) remained on colistin despite the availability of safer alternatives. No significant difference was observed in 30-day all-cause mortality between patients treated with colistin (0%) and those who were not (4.3%, p = 1.00). Similarly, the incidence of acute kidney injury did not differ significantly between the colistin group (0%) and the non-colistin group (p = 1.00). No significant difference was found in the hospital stay between colistin-treated patients (median 10.5 days, IQR [5.0–14.0]) and those not treated with colistin (median 13.0 days, IQR [7.0–21.0]), (p = 0.22). Conclusions: This study demonstrated that colistin was selectively initiated in high-risk patients, particularly those with XDR P. aeruginosa. However, its inappropriate continuation despite safer alternatives, as well as its discontinuation when no other options existed, raise concerns about antibiotic de-escalation practices. Interestingly, no significant differences in mortality or acute kidney injury were observed between patients who were treated with colistin and those who were not. These findings emphasize the need for antimicrobial stewardship programs and highlight the importance of large-scale trials to evaluate colistin’s efficacy and safety in MDR infections. - Exploring Antibiotic Resistance Patterns in Escherichia coli Isolates from Urinary Tract Infections: A Retrospective Study
Rama Alkhawaldeh, Lobna Gharaibeh, Amer Hayat Khan, Khawla Abu Hammour, Mohammed Zawiah, et al.
Journal of Clinical Medicine, 2025
Objectives: This retrospective analysis was conducted to update the antibiotic sensitivity profiles of Escherichia coli (E. coli) in urinary tract infections (UTIs) among adults (≥18 years) in Jordan. Methods: Data were collected from patients diagnosed with UTIs and confirmed by positive E. coli cultures between 1 January 2019 and 9 July 2021. The resistance patterns of E. coli to empiric antibiotics were assessed by matching the prescribed antibiotics with those tested, using clinical breakpoints to classify isolates as susceptible or resistant. Results: During the study, 230 patients with urine cultures confirming E. coli infection were included. Empiric antibiotics were prescribed to 87.4% (n = 201) of patients. Sensitivity testing was performed for 136 patients (59.1%), revealing that 62 patients (27%) had E. coli strains resistant to at least one antibiotic. Among the 236 empiric antibiotics prescribed, the appropriateness of 72 agents (30.5%) could not be determined owing to the absence of sensitivity testing. The culture results indicate that eight antibiotics (3.3%) did not provide adequate coverage against E. coli. Of the remaining 156 agents (66.1%) subjected to sensitivity testing, 89 (37.7%) were effective, while 67 (28.3%) were ineffective owing to bacterial resistance. Patients who underwent sensitivity tests performed had significantly longer hospital stays (10 days) than those who did not (8 days; p = 0.032). Female patients had a higher proportion of resistant E. coli isolates (51.5%) compared to males (30.8%, p = 0.036). Conclusions: This study highlights the importance of ongoing surveillance to guide empiric therapy and promote appropriate antibiotic use. Tailoring treatment based on patient-specific factors is essential to effectively managing antimicrobial resistance and improving clinical outcomes. - Evaluation of empiric therapy appropriateness, resistance patterns, and mortality in Pseudomonas aeruginosa infections in Jordan
Savana Sobh, Rania Itani, Khawla Abu Hammour, Rana K. Abu-Farha
Exploration of Medicine, 2025
Aim: This study aimed to investigate the susceptibility patterns of Pseudomonas aeruginosa strains, examine infection characteristics, and evaluate the appropriateness of empiric antibiotic therapy. Additionally, the study sought to identify factors influencing 30-day all-cause mortality in patients with Pseudomonas aeruginosa infections. Methods: This was a retrospective study conducted at Jordan University Hospital from January 2018 to March 2024. Adult patients (≥ 18 years) with confirmed Pseudomonas aeruginosa infections were included. Data were collected from medical records, focusing on demographics, infection characteristics, antibiotic treatment, and outcomes. The susceptibility patterns of Pseudomonas aeruginosa isolates were classified as multidrug-resistant (MDR) or non-MDR. Logistic regression was used to identify factors associated with 30-day mortality. Results: A total of 210 patients were included in the study, with 106 males (50.5%) and 104 females (49.5%). The majority of infections were community-acquired (n = 178, 84.8%), with the respiratory tract being the most common infection site (n = 81, 38.6%). Nearly half of the Pseudomonas aeruginosa isolates were MDR (n = 99, 47.1%). Empiric antibiotic therapy was administered to all patients, with imipenem-cilastatin (55.7%), vancomycin (35.7%), and piperacillin-tazobactam (26.7%) being the most commonly used antibiotics. Of the 210 patients, 32.4% (n = 68) received inappropriate empiric therapy. The 30-day all-cause mortality rate was 4.9% (n = 10). Multivariate analysis revealed that non-localized infections, such as bacteremia and sepsis, were strongly associated with increased mortality [adjusted odds ratio (AOR) = 17.455, P < 0.001]. Conclusions: This study highlights the high prevalence of MDR Pseudomonas aeruginosa infections, especially in community-acquired cases, and emphasizes the need for improved antimicrobial stewardship. The significant proportion of patients (32.4%) receiving inappropriate empiric therapy calls for better guidance in antibiotic prescribing practices. The key predictor of mortality was infection localization, indicating the importance of early intervention for systemic infections to reduce mortality rates. - Effectiveness of fluoroquinolone de-escalation in community-acquired pneumonia: impact on hospital stay and mortality
Aseel Abu Awad, Khawla Abu Hammour, Alaa Abuawad, Mohammed Zawiah, Rana K. Abu-Farha
Exploration of Medicine, 2025 - A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights
Khawla Abu Hammour, Adnan Abu Hamour, Faris El-Dahiyat, Mohammed Zawiah, Rana K. Abu-Farha
Therapeutic Advances in Gastroenterology, 2025 - Knowledge, attitude, and perception regarding the respiratory syncytial virus vaccine among healthcare professionals
Khawla Abu Hammour, Qusai Al Manaseer, Mariam Abdel-Jalil, Faris El-dahiyat, Walid Abu Hammour, et al.
Journal of Pharmaceutical Policy and Practice, 2025 - Treatment-related problems in neonates receiving parenteral nutrition: risk factors and implications for practice
Amal Akour, Lobna Gharaibeh, Omar El Khatib, Khawla Abu Hammour, Noor AlTaher, et al.
BMC Pediatrics, 2024 - Assessment of adherence to the Infectious Diseases Society of America guidelines for treating suspected meningitis in adults: A retrospective observational study
Dina Mohialdin, Rana Abu-Farha, Rama ALkhawaldeh, Fahmi Y Al-Ashwal, Khawla Abu Hammour
Journal of Pharmaceutical Health Services Research, 2024 - Machine learning assessment of vildagliptin and linagliptin effectiveness in type 2 diabetes: Predictors of glycemic control
Hanin A. Esaifan, Loai M. Saadah, Khawla Abu Hammour, Rana K. Abu Farha
Plos One, 2024 - Impact of COVID-19 on asthma and COPD patients’ hospital care: a lesson for future pandemics
Oriana Awwad, Suha AlMuhaissen, Mariam Abdel Jalil, Zaina Battah, Khawla Abu Hammour, et al.
Journal of Pharmaceutical Health Services Research, 2024 - Hospital pharmacists’ knowledge, attitudes and practice of pharmaceutical care and the barriers for its implementation at the hospital setting
Anan S. Jarab, Suhaib Muflih, Rawan Almomani, Shrouq Abu Heshmeh, Khawla Abu Hammour, et al.
Heliyon, 2024 - Audit of adherence to international guidelines (IDSA) in the treatment of infectious meningitis in pediatric patients in Jordan
Dina Mohialdin, Rana Abu-Farha, Rama ALkhawaldeh, Mohammed Zawiah, Khawla Abu Hammour
Current Medical Research and Opinion, 2024 - Occurrence and types of drug errors in voluntary reported incidents at a tertiary hospital in Jordan
Pharmacy Practice, 2024 - Cost-effectiveness of intravenous resuscitation fluids in sepsis patients: a patient-level data analysis in Jordan
Shoroq M. Altawalbeh, Eman M. Almestarihi, Rawand A. Khasawneh, Suleiman M. Momany, Khawla Abu Hammour, et al.
Journal of Medical Economics, 2024 - A retrospective analysis of the pharmacovigilance data registry in a tertiary teaching hospital in Jordan
Khawla Abu Hammour, Faris El-Dahiyat, Rund Hyari, Sara Salameh, Qusai Manaseer, et al.
Journal of Pharmaceutical Policy and Practice, 2024 - Knowledge, perception, and practice of health professions students and academics regarding halal pharmaceuticals: A cross-sectional study
Deema Jaber, Samaa Akram Al Tabbah, Lina Elsalem, Ahlam Zaid Alkilani, Eman Bani Omar, et al.
Journal of Infrastructure Policy and Development, 2024 - Detecting manuscripts written by generative AI and AI-assisted technologies in the field of pharmacy practice
Ammar Abdulrahman Jairoun, Faris El-Dahiyat, Ghaleb A. ElRefae, Sabaa Saleh Al-Hemyari, Moyad Shahwan, et al.
Journal of Pharmaceutical Policy and Practice, 2024 - Exploring Jordanian medical students’ perceptions and concerns about ChatGPT in medical education: a cross-sectional study
Adnan Abu Hammour, Khawla Abu Hammour, Hamza Alhamad, Razan Nassar, Faris El-Dahiyat, et al.
Journal of Pharmaceutical Policy and Practice, 2024
